Metformin: therapeutic option in people at high cardiometabolic risk
978-3-659-84209-2
3659842095
52
2016-09-05
36.90 €
eng
https://images.our-assets.com/cover/230x230/9783659842092.jpg
https://images.our-assets.com/fullcover/230x230/9783659842092.jpg
https://images.our-assets.com/cover/2000x/9783659842092.jpg
https://images.our-assets.com/fullcover/2000x/9783659842092.jpg
The topic of this book is prevention of type 2 diabetes mellitus and cardiovascular disease which are increasing by epidemic proportions all over the world. Metabolic syndrome is well established risk factor for type 2 diabetes mellitus and cardiovascular disease. Hyperinsulinaemia is considered as the earliest stage of development of type 2 diabetes and a core defect unifying the cardiovascular cluster of the metabolic syndrome. Treatment of the metabolic syndrome and hyperinsulinaemia is essential for the prevention of type 2 diabetes and cardiovascular disease. Metformin is a medication of first choice in therapeutic strategy of type 2 diabetes. The book comprises of two research articles representing results of metformin treatment in people at high risk for development of type 2 diabetes mellitus and cardiovascular disease such as those with hyperinsulinaemia, normal glucose tolerance and metabolic syndrome.
https://morebooks.de/books/tr/published_by/scholars-press/332258/products
Tıp
https://morebooks.de/store/tr/book/metformin:-therapeutic-option-in-people-at-high-cardiometabolic-risk/isbn/978-3-659-84209-2